Clinical trial · Interventional
Stereotactic Radiosurgery in Patients With Head and Neck Region Tumours
Escalating a Biological Dose of Radiation in the Target Volume Applying Stereotactic Radiosurgery in Patients With Head and Neck Region Tumours
NCT06472570CI-TRIAL-00078193recruitingN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The goal of this study is to evaluate the safety and efficacy of the stereotactic boost applied in patients with H\&N tumours.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Head and Neck Cancer | Malignant Head and Neck Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Stereotactic radiotherapy boost | Radiation | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Stereotactic radiotherapy
- description
- Patients treated with stereotactic radiosurgery boost. Treatment is conducted as radiotherapy alone or radiochemotherapy based on cisplatin
- interventionNames
- Radiation: Stereotactic radiotherapy boost
Primary outcomes (1)
- measure
- Response to treatment
- timeFrame
- one month after the end of treatment, every 3 months in the first year, every 4 months in the second year, and every six months in the third-fifth years
- description
- Response to treatment in imaging tests and clinical examination-local control (LC) and locoregional control (LRC).
Secondary outcomes (5)
- measure
- Evaluation of efficacy
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: 1. Patients with squamous cell carcinoma (SCC) or adenoid cystic carcinoma (ACC) of the H\&N region qualified for radical treatment with (definitive or adjuvant (adjuvant radiotherapy or radiochemotherapy in postoperative cases of R2 resection or early locoregional recurrence unsuitable for reoperation)) radiotherapy or radiochemotherapy. 2. Patients with other malignant tumours of the H\&N region (sarcomas, neuroendocrine carcinomas, differentiated carcinomas, undifferentiated carcinomas, or basaloid carcinomas) qualified for radical treatment with (definitive or adjuvant (adjuvant radiotherapy or radiochemotherapy in postoperative cases of R2 resection or early locoregional recurrence unsuitable for reoperation)) radiotherapy or radiochemotherapy. 3. Patients with nonmalignant tumours of the H\&N region (tumour mixtus or paraganglioma) demanding definitive or adjuvant radiotherapy. 4. Age: 18-80 years. Biomedicines 2022, 10, 1484 5 of 12 5. Performance status: Eastern Cooperative Oncology Group (ECOG) performance status score of 0-2. 6. Conscious agreement to participate in the clinical trial. Exclusion Criteria: 1. Do not meet the inclusion criteria. 2. Decompensated diabetes mellitus. 3. Myocardial infarction occurred up to 6 months before. 4. Pregnancy. 5. Mental disorder preclusive of making a conscious agreement
References
Publications (1)
- DERIVEDPolanowski P, Tukiendorf A, Nasiek A, Grzadziel A, Pietruszka A, Polanowska K, Rutkowski T, Skladowski K. High-dose stereotactic radiotherapy boost in the radical treatment of head and neck tumors. Radiat Oncol. 2026 May 29. doi: 10.1186/s13014-026-02857-2. Online ahead of print. PMID 42216211